Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis

Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis

Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by vasospasm and microvascular involvement. Iloprost (ILO), a prostaglandin analogous, is used for the treatment of SSc-related Raynaud’s phenomenon and digital ulcers. The suggested dose is 0.5–2 ng/kg/min for 6–8 h, and th...

Full description

Bibliographic Details
Main Authors: Riccardo Bixio, Giovanni Adami, Eugenia Bertoldo, Alessandro Giollo, Andrea Morciano, Davide Bertelle, Giovanni Orsolini, Luca Idolazzi, Maurizio Rossini, Ombretta Viapiana
Format: Article
Language:English
Published: SAGE Publishing 2022-11-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X221137125

Internet

https://doi.org/10.1177/1759720X221137125

Similar Items